Micafungin for the treatment of invasive aspergillosis

Journal of Infection

Volumn 68, Issue 6, 2014, Pages 507-526

  Enoch, D A ^a   Idris, S F ^a   Aliyu, S H ^a   Micallef, C ^a   Sule, O ^a   Karas, J A ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antifungal agents; Aspergillus spp.; Invasive aspergillosis; Micafungin

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ERYTHEMA MULTIFORME; FEBRILE NEUTROPENIA; HEPATOBILIARY DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; JAPAN; MONOTHERAPY; NAUSEA; NONHUMAN; PLASMA CELL DYSCRASIA; PROPHYLAXIS; RESPIRATORY FAILURE; REVIEW; SALVAGE THERAPY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; INVASIVE PULMONARY ASPERGILLOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LIPOPEPTIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899913899     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.01.007     Document Type: Review

References (115)

1. Viscoli C., Herbrecht R., Akan H., Baila L., Sonet A., Gallamini A., et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009, 64(6):1274-1281.
2. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44(10):1289-1297.
3. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
4. Herbrecht R., Maertens J., Baila L., Aoun M., Heinz W., Martino R., et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010, 45(7):1227-1233.
5. Espinel-Ingroff A. Invitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003, 20(4):121-136.
6. Nakai T., Uno J., Otomo K., Ikeda F., Tawara S., Goto T., et al. Invitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002, 48(2):78-81.
7. Nishiyama Y., Hasumi Y., Ueda K., Uchida K., Yamaguchi H. Effects of micafungin on the morphology of Aspergillus fumigatus. J Electron Microsc (Tokyo) 2005, 54(1):67-77.
8. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrobial Agents Chemother 2005, 49(4):1331-1336.
9. Nicasio A.M., Tessier P.R., Nicolau D.P., Knauft R.F., Russomanno J., Shore E., et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrobial Agents Chemother 2009, 53(3):1218-1220.
10. Hall R.G., Swancutt M.A., Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese and extremely obese people. Antimicrobial Agents Chemother 2011, 55:5107-5112.
11. Hirata Y., Aoyama T., Matsumoto Y., Ogawa F., Yamazaki H., Kikuti A., et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007, 127:897-901.
12. Fukuoka N., Imataki O., Ohnishi H., Kitanaka A., Kubota Y., Ishida T., et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2010, 42(7):2725-2730.
13. Inoue Y., Saito T., Ogawa K., Nishio Y., Kosugi S., Suzuki Y., et al. Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 2012, 50(11):831-837.
14. Nakagawa S., Kuwabara N., Kobayashi H., Shimoeda S., Ohta S., Yamato S. Simple column-switching HPLC method for determining levels of the antifungal agent micafungin in human plasma and application to patient samples. Biomed Chromatogr 2013, 27(5):551-555.
15. Kurtz M.B., Heath I.B., Marrinan J., Dreikorn S., Onishi J., Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrobial Agents Chemother 1994, 38(7):1480-1489.
16. Arikan S., Yurdakul P., Hascelik G. Comparison of two methods and three end points in determination of invitro activity of micafungin against Aspergillus spp. Antimicrobial Agents Chemother 2003, 47(8):2640-2643.
17. Antachopoulos C., Meletiadis J., Sein T., Roilides E., Walsh T.J. Comparative invitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrobial Agents Chemother 2008, 52(1):321-328.
18. Heyn K., Tredup A., Salvenmoser S., Muller F.M. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrobial Agents Chemother 2005, 49(12):5157-5159.
19. Imhof A., Balajee S.A., Marr K.A. New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol 2003, 41(12):5683-5688.
20. Martos A.I., Martin-Mazuelos E., Romero A., Serrano C., Gonzalez T., Almeida C., et al. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp. Diagn Microbiol Infect Dis 2012, 73(1):53-56.
21. Martos A.I., Romero A., Gonzalez M.T., Gonzalez A., Serrano C., Castro C., et al. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med Mycol 2010, 48(6):858-861.
22. Odabasi Z., Paetznick V., Rex J.H., Ostrosky-Zeichner L. Effects of serum on invitro susceptibility testing of echinocandins. Antimicrobial Agents Chemother 2007, 51(11):4214-4216.
23. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., Perlin D.S. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrobial Agents Chemother 2007, 51(6):2253-2256.
24. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Monzon A., Buitrago M.J., Rodriguez-Tudela J.L. Activity profile invitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrobial Agents Chemother 2009, 53(5):2192-2195.
25. Arabatzis M., Kambouris M., Kyprianou M., Chrysaki A., Foustoukou M., Kanellopoulou M., et al. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrobial Agents Chemother 2011, 55(6):3025-3030.
26. Tashiro M., Izumikawa K., Minematsu A., Hirano K., Iwanaga N., Ide S., et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrobial Agents Chemother 2012, 56(1):584-587.
27. Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011; application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013, 51:2571-2581.
28. Warn P.A., Morrissey G., Morrissey J., Denning D.W. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating invivo resistance to amphotericin B. J Antimicrob Chemother 2003, 51(4):913-919.
29. Gardiner R.E., Souteropoulos P., Park S., Perlin D.S. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005, 43(Suppl. 1):S299-S305.
30. Rocha E.M., Garcia-Effron G., Park S., Perlin D.S. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrobial Agents Chemother 2007, 51(11):4174-4176.
31. Arendrup M.C., Perkhofer S., Howard S.J., Garcia-Effron G., Vishukumar A., Perlin D., et al. Establishing invitro-invivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrobial Agents Chemother 2008, 52(10):3504-3511.
32. Wetzstein G.A., Green M.R., Greene J.N. Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases. J Infect 2007, 55(5):e131-e133.
33. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrobial Agents Chemother 2000, 44(3):614-618.
34. Matsumoto S., Wakai Y., Nakai T., Hatano K., Ushitani T., Ikeda F., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrobial Agents Chemother 2000, 44(3):619-621.
35. Petraitis V., Petraitiene R., Groll A.H., Roussillon K., Hemmings M., Lyman C.A., et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrobial Agents Chemother 2002, 46(6):1857-1869.
36. Clemons K.V., Espiritu M., Parmar R., Stevens D.A. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrobial Agents Chemother 2005, 49(12):4867-4875.
37. Lewis R.E., Albert N.D., Kontoyiannis D.P. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents Chemother 2008, 52(11):4178-4180.
38. Lewis R.E., Albert N.D., Kontoyiannis D.P. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008, 61(5):1140-1144.
39. Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species. J Chemother 2011, 23(2):102-106.
40. Ruiz-Cendoya M., Rodriguez M.M., Marine M., Pastor F.J., Guarro J. Invitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents 2008, 32(5):418-420.
41. Lewis R.E., Kontoyiannis D.P. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity invitro. J Antimicrob Chemother 2005, 56(5):887-892.
42. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., Walsh T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrobial Agents Chemother 2001, 45(12):3310-3321.
43. Ganesan L.T., Manavathu E.K., Cutright J.L., Alangaden G.J., Chandrasekar P.H. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect 2004, 10(11):961-966.
44. Brun Y.F., Dennis C.G., Greco W.R., Bernacki R.J., Pera P.J., Bushey J.J., et al. Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus invitro using a novel response surface paradigm. Antimicrobial Agents Chemother 2007, 51(5):1804-1812.
45. Ben-Ami R., Lewis R.E., Kontoyiannis D.P. Invitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods. Med Mycol 2011, 49(3):285-288.
46. Dennis C.G., Greco W.R., Brun Y., Youn R., Slocum H.K., Bernacki R.J., et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrobial Agents Chemother 2006, 50(2):422-427.
47. Luque J.C., Clemons K.V., Stevens D.A. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrobial Agents Chemother 2003, 47(4):1452-1455.
48. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187(12):1834-1843.
49. Clemons K.V., Parmar R., Martinez M., Stevens D.A. Efficacy of Abelcetalone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006, 58(2):466-469.
50. Clemons K.V., Stevens D.A. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006, 44(1):69-73.
51. Chandrasekar P.H., Cutright J.L., Manavathu E.K. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004, 10(10):925-928.
52. Graybill J.R., Bocanegra R., Gonzalez G.M., Najvar L.K. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003, 52(4):656-662.
53. Olson J.A., George A., Constable D., Smith P., Proffitt R.T., Adler-Moore J.P. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrobial Agents Chemother 2010, 54(9):3884-3894.
54. Takazono T., Izumikawa K., Mihara T., Kosai K., Saijo T., Imamura Y., et al. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrobial Agents Chemother 2009, 53(8):3508-3510.
55. Ibrahim A.S., Gebremariam T., Luo G., Fu Y., French S.W., Edwards J.E., et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrobial Agents Chemother 2011, 55(4):1768-1770.
56. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004, 36(5):372-379.
57. Izumikawa K., Ohtsu Y., Kawabata M., Takaya H., Miyamoto A., Sakamoto S., et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007, 45(3):273-278.
58. Kohno S., Izumikawa K., Kakeya H., Miyazaki Y., Ogawa K., Amitani R., et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011, 49(7):688-693.
59. Kohno S., Izumikawa K., Ogawa K., Kurashima A., Okimoto N., Amitani R., et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010, 61(5):410-418.
60. Kohno S., Izumikawa K., Yoshida M., Takesue Y., Oka S., Kamei K., et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013, 32(3):387-397.
61. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53(5):337-349.
62. Kontoyiannis D.P., Ratanatharathorn V., Young J.A., Raymond J., Laverdiere M., Denning D.W., et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009, 11(1):89-93.
63. Fujita M., Tao Y., Kajiki A., Ouchi H., Harada E., Ikegame S., et al. The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. J Infect Chemother 2012, 18(5):668-674.
64. Hanadate T., Wakasugi M., Sogabe K., Kobayashi T., Horita H., Kawamura I., et al. Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report. J Infect Chemother 2011, 17(5):622-632.
65. Kohno S., Niki Y., Amitani R. Clinical efficacy and safety of micafungin, a novel echinocandin antifungal drug in pulmonary aspergillosis in a postmarketing setting. Jpn J Chemother 2010, 58(2):128-139.
66. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006, 45(5):259-264.
67. Toubai T., Tanaka J., Ota S., Shigematsu A., Shono Y., Ibata M., et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2007, 46(1):3-9.
68. Goto N., Hara T., Tsurumi H., Ogawa K., Kitagawa J., Kanemura N., et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 2010, 85(11):872-876.
69. Kubiak D.W., Bryar J.M., Mcdonnell A.M., Delgado-Flores J.O., Mui E., Baden L.R., et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010, 32(4):637-648.
70. Maertens J., Marchetti O., Herbrecht R., Cornely O.A., Fluckiger U., Frere P., et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011, 46:709-718.
71. Freifield A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
72. Yamaguchi M., Kurokawa T., Ishiyama K., Aoki G., Ueda M., Matano S., et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol 2011, 90(10):1209-1217.
73. Yoshida M., Tamura K., Imamura M., Niitsu Y., Sasaki T., Urabe A., et al. Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Ann Hematol 2012, 91(3):449-457.
74. Racil Z., Toskova M., Kocmanova I., Buresova L., Kouba M., Drgona L., et al. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. Leuk Lymphoma 2013, 54(5):1042-1047.
75. Mizuno H., Sawa M., Yanada M., Shirahata M., Watanabe K., Kato T., et al. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study. Int J Hematol 2013, 98:231-236.
76. Hashino S., Morita L., Takahata M., Onozawa M., Nakagawa M., Kawamura T., et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008, 87(1):91-97.
77. Hiramatsu Y., Maeda Y., Fujii N., Saito T., Nawa Y., Hara M., et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008, 88(5):588-595.
78. Hirata Y., Yokote T., Kobayashi K., Nakayama S., Oka S., Miyoshi T., et al. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies. Leuk Lymphoma 2010, 51(5):853-859.
79. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10):1407-1416.
80. Carter N.J., Keating G.M. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs 2009, 11(4):271-291.
81. Glockner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. Eur J Med Res 2011, 16(4):167-179.
82. Salavert M., Jarque I. Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?. Enferm Infecc Microbiol Clin 2011, 29(Suppl. 2):43-49.
83. Huang X., Chen H., Han M., Zou P., Wu D., Lai Y., et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012, 18(10):1509-1516.
84. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D., Alexander B.D. Breakthrough invasive candidiasis in patients of micafungin. J Clin Microbiol 2010, 48:2373-2380.
85. Arrieta A.C., Maddison P., Groll A.H. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011, 30(6):e97-e102.
86. Chen Q., Lin M.H., Chen M.L., Liu Z.Y., Chai D., Wang R. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 2012, 125(2):345-351.
87. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360.
88. Astellas Pharma Inc. Funguard prescribing information October 2013, [15th version].
89. Ikeda F., Saika T., Sato Y., Suzuki M., Hasegawa M., Mikawa T., et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol 2009, 47(2):145-148.
90. Lockhart S.R., Zimbeck A.J., Baddley J.W., Marr K.A., Andes D.R., Walsh T.J., et al. Invitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrobial Agents Chemother 2011, 55(8):3944-3946.
91. Guinea J., Pelaez T., Alcala L., Ruiz-Serrano M.J., Bouza E. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrobial Agents Chemother 2005, 49(8):3495-3497.
92. Isham N., Ghannoum M.A. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006, 44(12):4342-4344.
93. Messer S.A., Jones R.N., Moet G.J., Kirby J.T., Castanheira M. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J Clin Microbiol 2010, 48(8):2984-2987.
94. Miyazaki M., Horii T., Hata K., Watanabe N.A., Nakamoto K., Tanaka K., et al. Invitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrobial Agents Chemother 2011, 55(10):4652-4658.
95. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Invitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009, 47(10):3323-3325.
96. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011, 69(1):45-50.
97. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., et al. Invitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrobial Agents Chemother 2000, 44(1):57-62.
98. Uchida K., Nishiyama Y., Yokota N., Yamaguchi H. Invitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000, 53(10):1175-1181.
99. Rudramurthy S.M., Chakrabarti A., Geertsen E., Mouton J.W., Meis J.F. Invitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis 2011, 71(4):370-377.
100. Shivaprakash M.R., Geertsen E., Chakrabarti A., Mouton J.W., Meis J.F. Invitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011, 54(5):e583-e589.
101. Tokimatsu I., Kushima H., Iwata A., Hashinaga K., Umeki K., Ohama M., et al. Invasive pulmonary aspergillosis with hematological malignancy caused by Aspergillus terreus and invitro susceptibility of A. terreus isolate to micafungin. Intern Med 2007, 46(11):775-779.
102. Alastruey-Izquierdo A., Cuesta I., Houbraken J., Cuenca-Estrella M., Monzon A., Rodriguez-Tudela J.L. Invitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med Mycol 2010, 48(1):97-102.
103. Santos R.P., Sanchez P.J., Mejias A., Benjamin D.K., Walsh T.J., Patel S., et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 2007, 26(4):364-366.
104. Takeda K., Morioka D., Matsuo K., Endo I., Sekido H., Moroboshi T., et al. A case of successful resection after long-term medical treatment of invasive pulmonary aspergillosis following living donor liver transplantation. Transplant Proc 2007, 39(10):3505-3508.
105. Okugawa S., Ota Y., Tatsuno K., Tsukada K., Kishino S., Koike K. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007, 39(4):344-346.
106. Ouchi H., Fujita M., Ikegame S., Inoshima I., Harada E., Nakanishi Y. Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin. J Infect Chemother 2007, 13(4):258-262.
107. Yamada R., Horikawa K., Ishihara S., Hoshino K., Kawaguchi T., Iyama K., et al. Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol 2010, 91(4):711-715.
108. Myoken Y., Sugata T., Fujita Y., Fujihara M., Iwato K., Murayama S.Y., et al. Early diagnosis and successful management of atypical invasive Aspergillus sinusitis in a hematopoietic cell transplant patient: a case report. J Oral Maxillofac Surg 2006, 64(5):860-863.
109. Ota S., Tanaka J., Kahata K., Toubai T., Kondo K., Mori A., et al. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol 2004, 79(4):390-393.
110. Kobayashi S., Murayama S., Tatsuzawa O., Koinuma G., Kawasaki K., Kiyotani C., et al. X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation. Eur J Pediatr 2007, 166(3):207-210.
111. Yokote T., Akioka T., Oka S., Fujisaka T., Yamano T., Hara S., et al. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol 2004, 83(1):64-66.
112. Hosono M., Hattori K., Shibata T., Sasaki Y., Hirai H., Suehiro S. Mycotic aneurysm of the distal aortic arch caused by Aspergillus. Jpn J Thorac Cardiovasc Surg 2006, 54(4):160-163.
113. Matsuda T., Koreeda Y., Mataki H., Taira T., Noma S., Higashimoto I. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid. Intern Med 2010, 49(12):1163-1169.
114. Saijo T., Izumikawa K., Takazono T., Kosai K., Kurihara S., Nakamura S., et al. A case of Legionella pneumophila pneumonia followed by invasive aspergillosis. Jpn J Infect Dis 2008, 61(5):379-381.
115. Yoshida K., Shoji H., Takuma T., Eguchi J., Imawari M., Niki Y. Iliopsoas abscess caused by Aspergillus fumigatus complicated by pulmonary aspergillosis. J Infect Chemother 2012, 18(4):569-575.